论文部分内容阅读
目的研究99mTc-ASON-EGF放射性药物在荷乳腺癌BALB/c裸鼠体内的分布及反义显像。方法制备99mTc-ASON-EGF,用SKBR-3细胞构建荷乳腺癌裸鼠模型;随后用放射性计数法测定其在荷乳腺癌BALB/c裸鼠体内的生物分布;最后在荷乳腺癌裸鼠模型中进行反义显像。结果99mTc-ASON-EGF经鼠尾静脉注射后0.5、1、2、4h,在乳腺癌组织中的%ID/g值分别是4.17、11.32、18.36、7.86;其中,2h最高,为18.36;同样,经鼠尾静脉注射0.5、1、2、4h后进行反义显像,2h效果最好。结论99mTc-ASON-EGF在体内具有良好的稳定性,在乳腺癌组织高浓聚,且在靶部位显像效果好,可望用于乳腺癌的显像诊断和治疗。
Objective To study the distribution and antisense imaging of 99mTc-ASON-EGF radiotherapy in breast-bearing BALB / c nude mice. Methods 99mTc-ASON-EGF was prepared and the breast cancer model was established by SKBR-3 cells. The biodistribution of 99mTc-ASON-EGF in nude mice bearing BALB / c nude mice was determined by radioactivity counting. In antisense imaging. Results The% ID / g values of 99mTc-ASON-EGF at 0.5, 1, 2 and 4 h after tail vein injection in mice were 4.17, 11.32, 18.36 and 7.86, respectively, of which the highest was at 2 h and 18.36 , Antisense imaging was performed after 0.5, 1, 2 and 4 h injection through the tail vein of mice, and the best effect was observed after 2 h. Conclusion 99mTc-ASON-EGF has good stability in vivo. It is highly concentrated in breast cancer tissues and has a good imaging effect at the target site. It is expected to be useful in the imaging diagnosis and treatment of breast cancer.